KalVista Pharmaceuticals (KALV) Stock

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. These inhibitors aim to address diseases with significant unmet medical needs. The company's core therapeutic strategy centers on its pipeline of small molecule plasma kallikrein inhibitors. These are specifically engineered to combat debilitating conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME), with several formulated as oral treatments. Key products in their portfolio include: KVD001, a plasma kallikrein inhibitor that has successfully concluded a Phase II clinical trial for the treatment of DME. Sebetralstat, which is currently advancing into the Phase 3 KONFIDENT trial, poised to become an oral, on-demand therapeutic option for acute HAE attacks. KVD824, another oral candidate in development for the management of HAE. A Factor XIIa oral inhibitor program, which is in its preclinical stage, targeting a specific enzyme implicated in HAE. The company's main offices are located in Cambridge, Massachusetts.

KalVista Pharmaceuticals is led by CEO Benjamin L. Palleiko, employs 150 people, headquartered in US, publicly traded since 2015.

KalVista Pharmaceuticals (KALV) stock trades at $27.00 with a market capitalization of $1.44B. The stock is valued at a price-to-earnings (P/E) ratio of -8.28, price-to-sales of 12.30. Over the past 52 weeks the stock has ranged between $9.83 and $27.00, and currently trades at its 52-week high.

On profitability, KalVista Pharmaceuticals generates a return on equity (ROE) of 5466.67% — well above the market average, a sign of a high-quality business, return on capital employed of 5733.33%, an operating margin of -232.43%, a net profit margin of -1.19%.